

## PHARMACY POLICY STATEMENT

### Ohio Medicaid

|                         |                              |
|-------------------------|------------------------------|
| <b>DRUG NAME</b>        | <b>Cinqair (reslizumab)</b>  |
| BILLING CODE            | J2786 (1 unit = 1 mg)        |
| BENEFIT TYPE            | Medical                      |
| SITE OF SERVICE ALLOWED | Office/Outpatient Hospital   |
| Coverage Requirements   | Prior Authorization Required |

Cinqair (reslizumab) is an IL-5 receptor blocker and monoclonal antibody. It was approved by the FDA in 2016 for the treatment of severe asthma.

Cinqair (reslizumab) will be considered for coverage when the following criteria are met:

#### Severe Asthma

For **initial** authorization:

1. Member is at least 18 years of age or older; AND
2. Medication must be prescribed by or in consultation with an allergist, immunologist, or pulmonologist; AND
3. Member has a blood eosinophil count of at least 300 cells/ $\mu$ L or at least 150 cells/ $\mu$ L if taking maintenance oral corticosteroids (OCS); AND
4. Member has at least two documented severe asthma exacerbations requiring oral corticosteroids (OCS), or at least one requiring hospitalization, within last year; AND
5. Member's asthma has been inadequately controlled after 3 months of conventional treatment on medium to high doses of inhaled corticosteroids (ICS) and long acting beta 2-agonists (LABA); AND
6. Medication is being used as add-on maintenance treatment to conventional therapies for asthma (i.e. ICS, LABA, etc.); AND
7. Medication is not used in conjunction with any other biologic therapy for asthma.
8. **Dosage allowed/Quantity limit:** 3mg/kg once every 4 weeks.

***If all the above requirements are met, the medication will be approved for 16 weeks.***

For **reauthorization**:

1. Medication not being used as monotherapy for asthma; AND
2. Chart notes have been provided that show the member has demonstrated improvement during 16 weeks of medication therapy:
  - a) Decreased frequency of emergency department visits or hospitalizations due to asthma exacerbations; OR
  - b) Increase in percent predicted FEV1 from pretreatment baseline; OR
  - c) Improved functional ability (i.e. decreased effect of asthma on ability to exercise, function in school or at work, or quality of sleep); OR
  - d) Decreased utilization of rescue medications or oral corticosteroids.

***If all the above requirements are met, the medication will be approved for an additional 12 months.***

**CareSource considers Cinqair (reslizumab) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.**

| DATE       | ACTION/DESCRIPTION   |
|------------|--|
| 05/18/2017 | New policy for Cinqair created. Lab for blood eosinophil count required within 4 weeks of dosing. Leukotriene receptor antagonists and corticosteroids on exacerbations taken out from criteria.   |
| 11/25/2020 | Eosinophil count was updated to be consistent with guidelines; exacerbation number was updated to be consistent with guidelines (2 requiring OCS or 1 requiring hospitalization in the last year); changed from not to be used with Nucala to not to be used with any other asthma biologic. |
| 02/24/2022 | Transferred to new template. Annual review; no changes   |

References:

1. Cinqair [package insert]. Frazer, PA: Teva Respiratory LLC; 2020.
2. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: Results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet Respir Med.* 2015;3(5):355-366.
3. Walford HH, Doherty TA. Diagnosis and management of eosinophilic asthma: a US perspective. *J Asthma Allergy.* 2014;7:53–65.
4. Difficult-To-Treat & Severe Asthma in Adolescent and Adult Patients: Diagnosis and Management. Global Initiative For Asthma (GINA); Apr. 2019. Available at: <https://ginasthma.org/wp-content/uploads/2018/11/GINA-SA-FINAL-wms.pdf>.
5. Kostikas K, Brindicci C, Patalano F. Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD. *Curr Drug Targets.* 2018;19(16):1882-1896. doi:10.2174/1389450119666180212120012
6. 2020 Focused Updates To The Asthma Management Guidelines. National Institute of Health; Dec 2020. Available at: <https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates>.

Effective date: 07/01/2022

Revised date: 02/24/2022